NAT Diagnostics, Inc. is developing a true Point-of-Care (POC) isothermal molecular diagnostic platform that achieves the following criteria:

  • Rapid results in under 10 minutes, directly from clinical samples
  • Low cost instrumentation (less than $800)
  • Simple to use, with no special user training
  • High accuracy
  • Meets the requirements for a CLIA-waiver

The initial target areas will be infectious disease, as there is a clear market opportunity for better POC diagnostics. Future target areas will include antibiotic resistance and oncology.

Licensing opportunities may be available outside of human diagnostics. Please inquire via